Viking Therapeutics Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX) Q1 2025 Earnings Call Transcript
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q1 2025 Results Conference Call April 23, 2025 4:30 PM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Asim Rana - Truist Securities Mike Ulz - Morgan Stanley Ryan Deschner - Raymond James Jay Olson - Oppenheimer Hardik Parikh - JPMorgan Mayank Mamtani - B. Riley Securities Annabel Samimy - Stifel Roger Song - Jefferies Andy Hsieh - William Blair Biren Amin - Piper Sandler Thomas Smith - Leerink Partners George Farmer - Scotiabank Yale Jen - Laidlaw & Company Jeet Mukherjee - BTIG Operator Welcome to the Viking Therapeutics First Quarter 2025 Financial Results Conference Call.
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Is Viking Therapeutics Stock (VKTX) Nearing A Bottom?
With earnings scheduled for the 23rd, Viking Therapeutic's (NASDAQ: VKTX) first-quarter investor call is expected to center around key pipeline updates. The spotlight will be on three clinical candidates: VK2735 (targeting obesity), VK2809 (for non-alcoholic steatohepatitis, or NASH), and VK0214 (for X-linked adrenoleukodystrophy, or X-ALD).
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $23.94, representing a +1.44% change from its previous close.
Viking Therapeutics: A Lot More Compelling After The Meltdown - Initiating Cautious Buy (Rating Upgrade)
VKTX's deep selloff from the 2024 heights have been well warranted indeed, given its pre-revenue status and ongoing cash burn, despite the promising GLP-1 candidates. It has also triggered the improved margin of safety and relatively compelling 2030 valuations, despite the recently downgraded forward estimates. This is significantly aided by the improved clarity surrounding VKTX's go-to-market strategy, as the management announces its first supply and manufacturing partnership.
Viking Therapeutics Stock Pops But Struggles to Hold Gains
Viking Therapeutics Inc. NASDAQ: VKTX has taken investors on a wild ride since the beginning of 2024. At one point, VKTX stock was up 375% from its closing price on January 2, 2024.
Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market
Viking Therapeutics, Inc. stock has dropped ~35% amid market volatility, but Pfizer's withdrawal of danuglipron boosts VK2735's prospects as a leading oral GLP-1 for obesity. Goldman Sachs' Neutral rating highlights risks like high entry barriers, competition, and potential need for additional financing, impacting VK2735's commercial viability. Despite strong Phase II data, VK2735 faces competition from innovative obesity treatments, and strategic partnerships or buyouts could be crucial for Viking's success.
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?
Viking Therapeutics (VKTX -0.99%) is operating in one of the highest-growth pharma areas around. I'm talking about the weight loss drug market -- one that Morgan Stanley analysts say may multiply by 15 to surpass $100 billion later this decade.
Viking Therapeutics, Inc. (VKTX) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $23.91, marking a -0.99% move from the previous day.
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.
Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.28, indicating a +1.14% shift from the previous trading day.
